Avacta’s FY25 update is one of those biotech results where the science is doing the heavy lifting. This is now a pure-play cancer therapeutics business after selling off the diagnostics operations, and the company is trying to convince investors that the real value sits in its pre|CISION platform – a drug delivery system designed to release cancer drugs around tumours while limiting damage to healthy tissue.
The broad message is positive on pipeline progress, but this is still a loss-making clinical-stage biotech that will need more money down the line. That means the opportunity is obvious, but so is the risk.
Avacta FY25 results show a cleaner oncology story after diagnostics disposals
Strategically, Avacta has simplified the business. It sold Launch Diagnostics Holdings for an upfront £12.9 million in March 2025 and Coris Bioconcept for an upfront £2.2 million in August 2025, leaving the group focused on oncology drug development.
For retail investors, that matters because the investment case is now much clearer. You are no longer looking at a mixed bag of diagnostics and therapeutics – you are backing a single biotech thesis centred on whether pre|CISION can produce meaningful clinical results.
That can be a good thing if the data land well. It can also make the shares more volatile because there is less diversification to cushion disappointment.
Avacta pre|CISION pipeline progress: AVA6000 and AVA6103 are the real share price drivers
The key assets are AVA6000 and AVA6103. Both are built on Avacta’s pre|CISION technology, which is a peptide drug conjugate – essentially a way of attaching a drug to a small targeting component so it is activated in the tumour environment rather than across the whole body.
AVA6000 salivary gland cancer data remains encouraging
AVA6000 is Avacta’s first-generation programme and a form of doxorubicin, a well-known chemotherapy drug with serious toxicity issues, especially around the heart. The company says it reported highly encouraging efficacy and safety data in salivary gland cancer, with a disease control rate of 90% maintained in the full cohort.
That is encouraging because Avacta is trying to prove a simple but valuable idea – keep the anti-cancer punch, cut the collateral damage. The RNS also says regulators agreed to remove the lifetime maximum dose limit due to favourable cardiac safety, which is a meaningful regulatory win if it holds up in later data.
More AVA6000 data from Phase 1a and 1b cohorts are expected in H1 2026. That should include updated efficacy data, salivary gland cancer expansion cohort information, and fuller cardiac safety details.
AVA6103 first patient dosed and late H2 2026 data could be a major catalyst
AVA6103 is probably the more exciting near-term programme for the market. This is Avacta’s second-generation candidate based on exatecan, and the first patient was treated in the FOCUS-01 Phase 1 trial in March 2026.
Why does that matter? Because AVA6103 uses a sustained release approach, meaning the payload is designed to be released over time in the tumour. In theory, that could improve exposure at the tumour site while reducing side effects in the rest of the body.
Avacta presented preclinical data comparing AVA6103 with successful antibody drug conjugates such as Enhertu and Datroway. Preclinical is not clinical, so nobody should get ahead of themselves, but the fact this programme has moved into human testing is important. Initial clinical data are expected in late H2 2026, and that looks like the biggest value inflection point in the next 9 to 12 months.
AVA6207 and IP growth add longer-term upside
The third-generation programme, AVA6207, is still earlier stage, but it adds optionality. Avacta says it has shown dual payload technology – meaning one tumour-targeting event could release two different drug payloads.
That is interesting because combination therapy is a big theme in oncology. Payload selection and clinical candidate selection for AVA6207 are expected in H2 2026.
The company also highlights more intellectual property filings around sustained release and dual payload delivery. In biotech, strong IP can matter almost as much as the early data because it protects future commercial value if the platform works.
Avacta FY25 financial results: stronger cash, but losses are still heavy
| Key figure | FY25 | FY24 |
|---|---|---|
| Reported revenue | £6.31 million | £24.42 million |
| Continuing operations revenue | £0.11 million | £0.11 million |
| Loss before tax from continuing operations | £36.84 million | £28.98 million |
| Research costs | £18.76 million | £14.27 million |
| Cash and cash equivalents at 31 December | £16.9 million | £12.9 million |
| Net assets | £2.48 million | £9.28 million |
The top line fell sharply, but that is mainly because diagnostics has been sold. The more relevant number now is continuing operations revenue, and that was only £0.11 million. In plain English, Avacta is not yet a meaningful revenue business on the therapeutics side.
Losses also worsened. Loss before tax from continuing operations increased to £36.84 million, while research costs rose to £18.76 million as the company pushed AVA6000 and AVA6103 forward.
That is not unusual for a biotech at this stage, but it does underline the reality: investors are paying for future possibility, not present earnings. If clinical data disappoint, there is not much else in the numbers to fall back on.
Avacta cash runway, fundraising and convertible bond risk matter more than usual
On the positive side, Avacta did improve its cash position. It raised £22.5 million in equity during 2025, then added another £10.0 million in an oversubscribed placing and subscription in March 2026.
Cash and short-term deposits were £16.9 million at 31 December 2025, and cash held at 30 April 2026 was £16.4 million. Management says that extends the cash runway into early Q1 2027.
That is helpful, but this is where investors need to read the small print. The going concern section explicitly says the group is dependent on raising funds to remain cash positive during the going concern period, that there are no agreements in place, and that a material uncertainty exists.
That is the biggest financial warning in the release. It does not mean a funding crisis is immediate, but it does mean more capital raising is likely unless partnering money arrives.
There is also the convertible bond to keep an eye on. At 31 December 2025, the carrying amount of the host debt liability was £13.36 million and the derivative liability was £2.79 million. This is a fairly complex financing structure, and repayments have already been made partly in shares, which means dilution for existing holders is part of the picture.
What Avacta FY25 means for retail investors now
My take is fairly straightforward. This was a good operational update wrapped inside a still-fragile financial profile.
- The bullish case: Avacta now has a cleaner oncology focus, two clinical-stage assets, encouraging AVA6000 signals, first-in-human progress for AVA6103, growing IP, and enough cash to reach important data readouts.
- The cautious case: revenue is tiny, losses are substantial, net assets are thin at £2.48 million, and further funding looks likely unless a partnership lands.
In other words, this is a classic biotech setup. If AVA6103 produces strong early human data in late H2 2026, the story could change quickly. If not, investors may end up focusing less on platform promise and more on financing risk.
For now, the science appears to be moving in the right direction. The balance sheet is better than it was, but it is not strong enough to remove funding risk. That makes the next set of clinical data absolutely central to the investment case.
